Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2909 studies found for:    "Carcinoma, Non-Small-Cell Lung"
Show Display Options
Rank Status Study
1 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
2 Completed Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Carcinoma, Non-Small Cell Lung;   Lung Neoplasms
Intervention: Drug: EKB-569
3 Recruiting Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer
Interventions: Drug: CC-223, erlotinib;   Drug: CC-223, oral azacitidine
4 Completed Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
5 Completed Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SGN-15;   Drug: Docetaxel
6 Not yet recruiting Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Intervention: Drug: Nintedanib
7 Terminated Sorafenib in Resected Non-small Cell Lung Carcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Sorafenib
8 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis
9 Completed An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Conditions: Carcinoma, Non-Small-Cell Lung;   Neoplasm Metastasis
Intervention: Drug: Cetuximab
10 Completed Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Condition: Non-Small-Cell Lung Carcinoma
Intervention: Drug: ILX651
11 Completed FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
Condition: Non-Small Cell Lung Carcinoma
Intervention: Drug: SGN-15, Docetaxel
12 Active, not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Vinorelbine Tartrate;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Pemetrexed Disodium;   Biological: Bevacizumab;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
13 Completed FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Intervention: Drug: FR901228
14 Recruiting Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Condition: Non Small Cell Lung Carcinoma
Intervention:
15 Not yet recruiting Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Conditions: Carcinoma, Non-Small Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Intervention: Drug: Pazopanib
16 Unknown  Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Lung Cancer;   Stage IIIA Non Small Cell Lung Cancer;   Stage IIIB Non Small Cell Lung Cancer
Intervention: Drug: S-3304
17 Recruiting Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
Conditions: HIV Infection;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
18 Recruiting Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Drug: Irinotecan Hydrochloride;   Drug: Gemcitabine Hydrochloride;   Drug: Docetaxel;   Drug: Pemetrexed Disodium;   Other: Laboratory Biomarker Analysis
19 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
20 Terminated Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
Conditions: Carcinoma, Non-small Cell Lung;   Lung Cancer
Intervention: Drug: Satraplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years